PFAS linkage
- The liver is a primary organ for toxicology research involving PFAS, with studies reporting associations with liver enzymes, fatty liver markers, and metabolic changes.
- Some studies have examined PFAS exposure and liver cancer risk, particularly in relation to long-term body burden and liver injury pathways.
- Because liver cancer has several established causes, intake review requires detailed medical and exposure documentation.
Liver cancer symptoms
- Unexplained weight loss or loss of appetite
- Upper abdominal pain, swelling, or a feeling of fullness
- Yellowing of the skin or eyes
- Nausea, vomiting, fatigue, or weakness
- Easy bruising, dark urine, pale stools, or worsening liver disease symptoms
Diagnosis and medical records
- Blood tests including liver function tests and AFP when appropriate
- Ultrasound, CT, MRI, or contrast-enhanced imaging of the liver
- Biopsy in selected cases when imaging and blood tests are not definitive
- Staging tests to assess liver function, tumor burden, and spread
Treatment options
- Surgical resection or liver transplant for selected localized cases
- Ablation, embolization, chemoembolization, or radioembolization
- Immunotherapy, targeted therapy, or systemic therapy for advanced disease
- Supportive care to manage cirrhosis, pain, nutrition, or bile-duct complications
What patients should gather for intake
- Keep imaging reports, biopsy or pathology results, AFP levels, liver-function records, and oncology summaries.
- Include history of hepatitis, cirrhosis, fatty liver disease, alcohol-related liver disease, or transplant evaluation.
- Document PFAS exposure sources, especially long-term contaminated water or occupational contact.
Medical and attorney advertising notice. This page is for general information only and is not medical advice. Talk with your treating clinician about diagnosis and treatment. Submitting an intake form does not create an attorney-client relationship, and cases may be referred to qualified national PFAS co-counsel.